Besremi (Ropeginterferon
- Medicine Name: Besremi
- Generic Name: Ropeginterferon alfa-2b-njft
- Dosage Form & Strength: Injection: 500 mcg/mL solution in a single-dose prefilled syringe
- Manufactured By: PharmaEssentia Corporation
Besremi is an interferon alfa-2b used for the treatment of adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells.
Recommended Dosage: The recommended starting dose is 100 mcg by subcutaneous injection every 2 weeks (50 mcg if receiving hydroxyurea). Increase the dose of besremi injection by 50 mcg every 2 weeks (up to a maximum of 500 mcg) until hematological parameters are stabilized. Interrupt or discontinue dosing in case certain adverse reactions occur.
- Severe or fatal neuropsychiatric reactions have occurred in patients receiving interferon alfa products, including Ropeginterferon alfa-2b-njft.
- Precisely assess patients for any symptoms of psychiatric disorders and consider psychiatric consultation and treatment if such symptoms occurs. In case psychiatric symptoms worsen, it is recommended to discontinue besremi 500 mcg therapy.
- Endocrine toxicity has emerged in patients taking treatment with interferon alfa products, including Ropeginterferon alfa-2b-njft. Do not use this drug in patients with active serious or untreated endocrine disorders associated with autoimmune disease.
- Assess thyroid function in patients who develop signs/symptoms suggestive of thyroid disease during Ropeginterferon alfa-2b-njft therapy. Discontinue this therapy in patients who develop endocrine disorders that are difficult to manage during treatment.
- Reduced peripheral blood counts have noted in patients taking treatment with interferon alfa products, including besremi 500 mcg injection. Monitor complete blood counts, during titration and every 3 to 6 months during the maintenance phase. Assess patients for signs/symptoms of infection or bleeding.
- Hyperlipidemia has emerged in patients treated with interferon alfa products, including Ropeginterferon alfa-2b-njft. Assess serum triglycerides prior to and during therapy and manage when elevated.
- Pregnancy testing is recommended prior to Ropeginterferon alfa-2b-njft treatment in females of reproductive age or potential.
What documents are required to import BESREMi to India?
BESREMi (ropeginterferon alfa 2b njft) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription letter from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by Gov of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is BESREMi available in India?
BESREMi (ropeginterferon alfa 2b njft injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of besremi in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
BESREMi can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of BESREMi (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for besremi 500 mcg price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements
Indian Pharma Network is able to source the BESREMi (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Besremi®?
Ropeginterferon alfa-2b-njft is Generic Name for the trade name drug Besremi®.
What is the Manufacturer Name of Besremi®?
Besremi® is manufactured by PharmaEssentia Corporation.
Is Besremi® approved by the FDA?
Yes, Besremi® is approved by the FDA. Date of approval: November 12, 2021.
What is Besremi®?
Besremi is the first medicine in its class that’s approved by the FDA to treat adults with Polycythemia vera (PV). Polycythemia vera is a blood disorder that causes bones to make excess red blood cells.
How much does Besremi® cost in India?
The besremi cost in India is absolutely reasonable. To procure this polycythemia vera medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What is the dosage and form of Besremi® supplied?
Besremi® is supplied as Injection: 500 mcg/mL solution in a single-dose prefilled syringe for subcutaneous administration.
What are the most common side effects due to Besremi®?
Most common besremi side effects include: fatigue, influenza-like illness, arthralgia, nasopharyngitis, musculoskeletal pain, and pruritus.
What are the storage conditions of Besremi®?
Store in a refrigerator at 36-46°F (2-8°C) in the original carton in order to protect from light. Do not freeze.
What are the Highlights of prescribing information for Besremi®?
Click Here to download full Besremi prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.